Oral GLP-1 drug orforglipron shows promising safety profile in Japanese type 2 diabetes patients

A new phase 3 trial published in The Lancet Diabetes & Endocrinology found that orforglipron — an oral GLP-1 receptor agonist — has an acceptable safety profile for Japanese adults with type 2 diabetes (T2D). The ACHIEVE-J trial followed 401 patients across 40 centers in Japan over 52 weeks, testing three once-daily doses (3 mg, 12 mg, and 36 mg) as add-on therapy to diet and exercise or existing oral antihyperglycemic medications.

Most treatment-emergent adverse events were mild or moderate, with gastrointestinal symptoms being the primary reason for discontinuation. The drug also delivered meaningful reductions in blood sugar and body weight — a dual benefit that's especially relevant for East Asian populations, who often develop diabetes at lower BMIs.

By the Numbers:

• 85% of participants experienced treatment-emergent adverse events (mostly mild or moderate)
• HbA1c reductions: -1.7%, -2.0%, and -2.1% for 3 mg, 12 mg, and 36 mg groups, respectively
• Body weight reductions: -2.0 kg, -4.7 kg, and -6.0 kg across dose groups
• Up to 59.9% of participants in the 36 mg group achieved ≥5% body weight loss
• Discontinuation due to adverse events: 5%, 8%, and 14% across dose groups

Why it matters: With limited data on GLP-1 therapies in East Asian populations, this trial fills a critical gap. Orforglipron's oral formulation and favorable safety profile could make it a practical new treatment option for Japanese patients with T2D.